July 2020

BCG: a therapeutic modality for COVID-19 and cancers

The Bioidea group invites you to join healthcare, biotech and investment community for the virtual session featuring distinguished clinicians and scientists working on the BCG vaccine for COVID-19 and cancer. Our webinar will also discuss how BCG modality can be exploited to construct next-generation genetically-engineered therapies. Event is to be live streamed to multiple platforms.

Bacillus Calmette–Guérin (BCG) is a live attenuated vaccine that was developed against tuberculosis at the beginning of the 20th century. BCG is also approved as a treatment for early-stage baldder cancer. The recent studies revealed a correlation showing that countries with higher rates of BCG vaccinations had lower peak mortality rates from COVID-19. Receiving BCG vaccination during early childhood is associated with reduced risk of subsequent lung cancer development. These beneficial effect of BCG against viral infections are proposed to be mediated by the stimulation of innate immune mechanisms, also termed trained immunity

WHEN: Wednesday July 22, 4:15 – 5:00 PM ET 

WHERE: ZOOM (link to be send to registered / vetted participants)

RSVP to register and receive Zoom link: https://bcg-vaccine-advances.eventbrite.com

Panelists

Dr. Leonardo O. Reis, MD PhD. Professor Livre Docente Urologia
Produtividade Pesquisa CNPq, UroScience / Urology / Oncology
Dr Seth Lerner, MD. Professor of Urology. Beth and Dave Swalm Chair in Urologic Oncology
Director of Urologic Oncology, Director of the Multidisciplinary Bladder Cancer Program
Urology, Baylor College of Medicine, Houston, TX, US
Dr Andrew DiNardo, MD. Assistant Professor. Medicine-Infectious Disease, Baylor College of Medicine Houston, TX, US
Dr Ashish Kamat, MD. Professor of Urologic Oncology. Wayne B. Duddlesten Professor of Cancer Research, Attending Surgeon, Department of Urology, Division of Surgery, The University of Texas, MD Anderson Cancer Center
Dr Jessica Seeliger, PhD. Associate Professor, Department of Pharmacological Sciences, Stony Brook University. Microbial Pathogenesis.
Dr Yossef Av-Gay, PhD. Professor, Division Of Infectious Diseases, The University Of British Columbia
Dr Lewis Schrager, MD. Infectious Diseases, TB. Former VP, Scientific Affairs at Aeras
Dr Naomi E. Aronson, MD. Professor of Medicine , Director, Infectious Diseases Division , Uniformed Services University of the Health Sciences
Dr Jordi Orchando, PhD. Assistant Professor, Oncological Sciences, The Icahn School of Medicine at Mount Sinai
Dr Boris Shor, PhD. Manhattan BioSolutions, Inc. Founder & CEO

The views expressed by Dr. Aronson are those of the presenter and do not reflect the official 
policy or position of her institution (the Uniformed Services University), the Department of Defense or the US government
Event Moderators
Dr Navpaul Singh, MD. Chief Medical Consultant, Nascent Biotechnology

Selected Clinical Trails Assessing BCG For COVID-19

- BCG Vaccine for Health Care Workers as Defense Against COVID 19 (BADAS)
  NCT04348370,United States
- COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin 
  Enhancement (BATTLE)
  NCT04369794, Brazil
- Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and 
  Severity (COBRA)
  NCT04439045, Canada
- Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
  NCT04373291, Denmark
- BCG Vaccination for Healthcare Workers in COVID-19 Pandemic
  NCT04379336, South Africa
- BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE)
  NCT04327206, Australia
- Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate 
  Immunity in Health Care   Workers (COVID-BCG)
  NCT04384549, France
- Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine 
  (BCG-CORONA)
  NCT04328441, Netherlands
- Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 
  Pandemic
  NCT04387409, Germany
- Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory 
  Infectious Diseases in Elderly in COVID-19 Pandemic
  NCT04435379, Germany